Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease

BMC Gastroenterology

Volumn 12, Issue , 2012, Pages

  El Hodhod, Mostafa A ^a   Hamdy, Ahmad M ^a   Abbas, Amal A ^a   Moftah, Sherine G ^a   Ramadan, Alhag Ahmed M ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b MINISTRY OF HEALTH   (Egypt)

Author keywords

Bone mineral density; Children; FGF23; IBD

Indexed keywords

ALKALINE PHOSPHATASE; AMINOSALICYLIC ACID; CALCITRIOL; CALCIUM; COLECALCIFEROL; CREATININE; FIBROBLAST GROWTH FACTOR 23; INFLIXIMAB; PARATHYROID HORMONE; PHOSPHORUS; PREDNISONE; FIBROBLAST GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ADOLESCENT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROHN DISEASE; DENSITOMETRY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEMALE; HUMAN; ILEOANAL ANASTOMOSIS; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL SUPPORT; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHYSICAL ACTIVITY; PROCTOCOLECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REMISSION; SCHOOL CHILD; SEQUENCE HOMOLOGY; ULCERATIVE COLITIS; FOLLOW UP; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; BONE DENSITY; CALCIUM; CASE-CONTROL STUDIES; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; OSTEOPOROSIS; PARATHYROID HORMONE; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN D;

EID: 84860338347     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-12-44     Document Type: Article

References (55)

1. Sylvester FA, Wyzga N, Hyams JS, Davis PM, Lerer T, Vance K. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis 2007, 13(1):42-50. 10.1002/ibd.20006, 17206638.
2. Cowan FJ, Warner JT, Dunstan FD, Evans WD, Gregory JW, Jenkins HR. Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child 1997, 76(4):325-329. 10.1136/adc.76.4.325, 1717165, 9166024.
3. Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis 2010, 13(3):259-265. 10.1111/j.1756-185X.2010.01542.x, 20704624.
4. Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F, Passariello R. Cucchiara S Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2007, 13(4):416-423. 10.1002/ibd.20039, 17206686.
5. Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Steinhart H, Greenberg G. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2005, 3(2):122-132. 10.1016/S1542-3565(04)00663-9, 15704046.
6. Hessov I, Mosekilde L, Melsen F, Fasth S, Hultén L, Lund B, Lund B, Sørensen OH. Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease. Scand J Gastroenterol 1984, 19(5):691-696.
7. Bernstein CN, Bector S, Leslie WD. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am J Gastroenterol 2003, 98(11):2468-2473. 10.1111/j.1572-0241.2003.07676.x, 14638350.
8. Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 2004, 53(8):1129-1136. 10.1136/gut.2003.036657, 1774134, 15247180.
9. Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996, 10(5):777-786. 10.1046/j.1365-2036.1996.63205000.x, 8899087.
10. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, 98(11):6500-6505. 10.1073/pnas.101545198, 33497, 11344269.
11. Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, Yamashita T, Miyamoto Y, Okazaki H, Nakamura K, Nakahara K, Fukumoto S, Fujita T. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004, 89(8):3979-3982. 10.1210/jc.2004-0406, 15292336.
12. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H. Fibroblast growth factor 23 in oncogenic osteomalacia and Xlinked hypophosphatemia. N Engl J Med 2003, 348:1656-1663. 10.1056/NEJMoa020881, 12711740.
13. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002, 143(8):3179-3182. 10.1210/en.143.8.3179, 12130585.
14. Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, Schiavi SC, Slatapolsky E, Brown AJ. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006, 104(1):p23-p32. 10.1159/000093277, 16691036.
15. Bowe AE, Finnegan R, de Beur SM J, Cho J, Levine MA, Kumar R, Schiavi SC. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001, 284:977-981. 10.1006/bbrc.2001.5084, 11409890.
16. Xia W, Meng X, Jiang Y, Li M, Xing X, Pang L, et al. Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets. Calcif Tissue Int 2007, 81(6):415-420. Epub 2007 Nov 29, 10.1007/s00223-007-9067-4, 18046499.
17. Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998, 43:203-209. 10.1136/gut.43.2.203, 1727225, 10189845.
18. Uno JK, Kolek OI, Hines ER, Xu H, Timmermann BN, Kiela PR, Ghishan FK. The role of tumor necrosis factor alpha in down-regulation of osteoblast Phex gene expression in experimental murine colitis. Gastroenterology 2006, 131(2):497-509. 10.1053/j.gastro.2006.05.020, 16890604.
19. Working IBD. Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.: Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005, 41(1):1-7. 10.1097/01.MPG.0000163736.30261.82, 15990620.
20. Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart AH, Griffiths A. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007, 133(2):423-432. Epub 2007 May 21, 10.1053/j.gastro.2007.05.029, 17681163.
21. Shepanski MA, Markowitz JE, Mamula P, Hurd LB, Baldassano RN. Is an abbreviated Pediatric Crohn's disease activity index better than the original?. J Pediatr Gastroenterol Nutr 2004, 39:68-72. 10.1097/00005176-200407000-00014, 15187784.
22. WHO a: Child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development 2006, WHO, Geneva, WHO.
23. Wadsworth C, Wadsworth E. Efficacy of latex agglutination and quantification methods for determination of C-reactive protein (CRP) in pediatric sera. Clin Chim Acta 1984, 138(3):309-318. 10.1016/0009-8981(84)90138-4, 6426825.
24. Ray AK. A safe and inexpensive method for setting up the Westergren ESR. J Clin Pathol 1972, 25(4):366. 10.1136/jcp.25.4.366, 477315, 5028646.
25. Chapoteau E, Czech BP, Zazulak W, Kumar A. New reagent for colorimetric assay of calcium in serum. Clin Chem 1993, 39(9):1820-1824.
26. Rubino L, Catapano V, Guerra G. Determination of inorganic phosphorus in serum: Evaluation of three methods applied to the Technicon RA-1000 analyzer. J Automat Chem 1989, 11(4):164-167. 10.1155/S1463924689000350, 2547801, 18925248.
27. Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL. Determination of vitamin D status by radioimmunoassay with an125I-labeled tracer. Clin Chem 1993, 39:529-533.
28. Sentongo TA, Semaeo EJ, Stettler N, Piccoli DA, Stallings VA, Zemel BS. Vitamin D status in children, adolescents, and young adults with Crohn's disease. Am J Clin Nutr 2002, 76:1077-1081.
29. Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004, 158:531-537. 10.1001/archpedi.158.6.531, 15184215.
30. Clive DR, Sudhaker D, Giacherio D, Gupta M, Schreiber MJ, Sackrison JL, MacFarlane GD. Analytical and clinical validation of a radioimmunoassay for the measurement of 1,25 dihydroxy vitamin D. Clin Biochem 2002, 35(7):517-521. 10.1016/S0009-9120(02)00378-8, 12493579.
31. Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006, 91(6):2055-2061. Epub 2006 Mar 21, 10.1210/jc.2005-2105, 16551733.
32. van der Sluis IM, de Ridder MA, Boot AM, Krenning EP, de Muinck Keizer-Schrama SM. Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults. Arch Dis Child 2002, 87:341-347. 10.1136/adc.87.4.341, 1763043, 12244017.
33. Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of Hand and Wrist 1959, Stanford University Press, Stanford.
34. Barnes C, Wong P, Egan B, Cameron F, Jones G, Ekert H, Monagle P. Reduced bone density among children with severe hemophilia. Pediatrics 2004, 114:177-181. 10.1542/peds.114.1.177, 15231925.
35. Buller H, Chin S, Kirschner B, Kohn J, Markowitz J, Moore D, Murch S, Taminiau J. Inflammatory Bowel Disease in Children and Adolescents: Working Group Report of the First World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2002, 35:S151-S158.
36. D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999, 116:1029-1034. 10.1016/S0016-5085(99)70005-3, 10220494.
37. Alexander F, Sarigol S, DiFiore J. Fate of the pouch in 151 pediatric patients after ileal pouch anal anastomosis. J Pediatr Surg 2003, 38(1):78-82. 10.1053/jpsu.2003.50015, 12592624.
38. Semeao EJ, Jawad AF, Zemel BS, Neiswender KM, Piccoli DA, Stallings VA. Bone mineral density in children and young adults with Crohn's disease. Inflamm Bowel Dis 1999, 5:161-166.
39. Levine A, Mishna L, Ballin A, Givoni S, Dinari G, Hartman C. Use of Quantitative Ultrasound to Assess Osteopenia in Children With Crohn's Disease. J Pediatr Gastroenterol Nutr 2002, 35:169-172. 10.1097/00005176-200208000-00012, 12187292.
40. Schmidt S, Mellström D, Norjavaara E, Sundh SV, Saalman R. Low bone mineral density in children and adolescents with inflammatory bowel disease: A population-based study from Western Sweden. Inflamm Bowel Dis 2009, 15(12):1844-1850. 10.1002/ibd.20962, 19408319.
41. Herzog D, Bishop N, Glorieux F, Seidman EG. Interpretation of bone mineral density values in pediatric Crohn's disease. Inflamm Bowel Dis 1998, 4:261-267. 10.1002/ibd.3780040402, 9836077.
42. Ahmed SF, Horrocks IA, Patterson T, Zaidi S, Ling SC, McGrogan P. Bone mineral assessment by dual energy X-ray absorptiometry in children with inflammatory bowel disease: evaluation by age or bone area. J Pediatr Gastroenterol Nutr 2004, 38:276-281. 10.1097/00005176-200403000-00008, 15076625.
43. Viapiana O, Gatti D, Dalle Grave R, Todesco T, Rossini M, Braga V, et al. Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight. Bone 2007, 40(4):1073-1077. Epub 2007 Jan 19, 10.1016/j.bone.2006.11.015, 17240212.
44. Bhambri R, Naik V, Malhotra N, Taneja S, Rastogi S, Ravishanker U, et al. Changes in bone mineral density following treatment of osteomalacia. J Clin Densitom 2006, 9(1):120-127. Epub 2006 Mar 27, 10.1016/j.jocd.2005.11.001, 16731441.
45. Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr 2008, 87(4):1087S-1091S.
46. Fukumoto S. Post-translational modification of Fibroblast Growth Factor 23. Ther Apher Dial 2005, 9(4):319-322. 10.1111/j.1744-9987.2005.00289.x, 16076374.
47. Yamamoto R, Minamizaki T, Yoshiko Y, Yoshioka H, Tanne K, Aubin JE, et al. 1 alpha,25-dihydroxyvitamin D3 acts predominately in mature osteoblasts under conditions of high extracellular phosphate to increase fibroblast growth factor 23 production in vitro. J Endocrinol 2010, 206(3):279-286. Epub 2010 Jun 8, 10.1677/JOE-10-0058, 2917591, 20530653.
48. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004, 19:429-435.
49. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117:4003-4008. 2066196, 17992255.
50. Walther F, Fusch C, Radke M, Beckert S, Findeisen A. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. J Pediatr Gastroenterol Nutr 2006, 43(1):42-51. 10.1097/01.mpg.0000228105.91240.80, 16819376.
51. Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 2004, 20(6):607-614. 10.1111/j.1365-2036.2004.02152.x, 15352908.
52. Ryan BM, Russel MG, Schurgers L, Wichers M, Sijbrandij J, Stockbrugger RW, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther 2004, 20(8):851-857. 10.1111/j.1365-2036.2004.02097.x, 15479356.
53. Ghishan FK, Kiela PR. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol 2011, 300:G191-G201. 10.1152/ajpgi.00496.2010, 3043650, 21088237.
54. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994, 9:1137-1141.
55. Sylvester FA. IBD and skeletal health: children are not small adults!. Inflamm Bowel Dis 2005, 11:1020-1023.